Mutational landscape and antiproliferative functions of ELF transcription factors in human cancer

Mizuo Ando, Masahito Kawazu, Toshihide Ueno, Daizo Koinuma, Koji Ando, Junji Koya, Keisuke Kataoka, Takahiko Yasuda, Hiroyuki Yamaguchi, Kazutaka Fukumura, Azusa Yamato, Manabu Soda, Eirin Sai, Yoshihiro Yamashita, Takahiro Asakage, Yasushi Miyazaki, Mineo Kurokawa, Kohei Miyazono, Stephen D Nimer, Tatsuya YamasobaHiroyuki Mano

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

ELF4 (also known as MEF) is a member of the ETS family of transcription factors. An oncogenic role for ELF4 has been demonstrated in hematopoietic malignancies, but its function in epithelial tumors remains unclear. Here, we show that ELF4 can function as a tumor suppressor and is somatically inactivated in a wide range of human tumors. We identified a missense mutation affecting the trans activation potential of ELF4 in oral squamous cell carcinoma cells. Restoration of the trans activation activity through introduction of wild-type ELF4 significantly inhibited cell proliferation in vitro and tumor xenograft growth. Furthermore, we found that ELF1 and ELF2, closely related transcription factors to ELF4, also exerted antiproliferative effects in multiple cancer cell lines. Mutations in ELF1 and ELF2, as in ELF4, were widespread across human cancers, but were almost all mutually exclusive. Moreover, chromatin immunoprecipitation coupled with high-throughput sequencing revealed ELF4-binding sites in genomic regions adjacent to genes related to cell-cycle regulation and apoptosis. Finally, we provide mechanistic evidence that the antiproliferative effects of ELF4 were mediated through the induction of HRK, an activator of apoptosis, and DLX3, an inhibitor of cell growth. Collectively, our findings reveal a novel subtype of human cancer characterized by inactivating mutations in the ELF subfamily of proteins, and warrant further investigation of the specific settings where ELF restoration may be therapeutically beneficial.

Original languageEnglish (US)
Pages (from-to)1814-1824
Number of pages11
JournalCancer Research
Volume76
Issue number7
DOIs
StatePublished - Apr 1 2016

Fingerprint

Transcription Factors
Neoplasms
Apoptosis
Growth Inhibitors
Mutation
Chromatin Immunoprecipitation
Hematologic Neoplasms
Missense Mutation
Heterografts
Squamous Cell Carcinoma
Cell Cycle
Binding Sites
Cell Proliferation
Cell Line
Growth
Genes
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ando, M., Kawazu, M., Ueno, T., Koinuma, D., Ando, K., Koya, J., ... Mano, H. (2016). Mutational landscape and antiproliferative functions of ELF transcription factors in human cancer. Cancer Research, 76(7), 1814-1824. https://doi.org/10.1158/0008-5472.CAN-14-3816

Mutational landscape and antiproliferative functions of ELF transcription factors in human cancer. / Ando, Mizuo; Kawazu, Masahito; Ueno, Toshihide; Koinuma, Daizo; Ando, Koji; Koya, Junji; Kataoka, Keisuke; Yasuda, Takahiko; Yamaguchi, Hiroyuki; Fukumura, Kazutaka; Yamato, Azusa; Soda, Manabu; Sai, Eirin; Yamashita, Yoshihiro; Asakage, Takahiro; Miyazaki, Yasushi; Kurokawa, Mineo; Miyazono, Kohei; Nimer, Stephen D; Yamasoba, Tatsuya; Mano, Hiroyuki.

In: Cancer Research, Vol. 76, No. 7, 01.04.2016, p. 1814-1824.

Research output: Contribution to journalArticle

Ando, M, Kawazu, M, Ueno, T, Koinuma, D, Ando, K, Koya, J, Kataoka, K, Yasuda, T, Yamaguchi, H, Fukumura, K, Yamato, A, Soda, M, Sai, E, Yamashita, Y, Asakage, T, Miyazaki, Y, Kurokawa, M, Miyazono, K, Nimer, SD, Yamasoba, T & Mano, H 2016, 'Mutational landscape and antiproliferative functions of ELF transcription factors in human cancer', Cancer Research, vol. 76, no. 7, pp. 1814-1824. https://doi.org/10.1158/0008-5472.CAN-14-3816
Ando, Mizuo ; Kawazu, Masahito ; Ueno, Toshihide ; Koinuma, Daizo ; Ando, Koji ; Koya, Junji ; Kataoka, Keisuke ; Yasuda, Takahiko ; Yamaguchi, Hiroyuki ; Fukumura, Kazutaka ; Yamato, Azusa ; Soda, Manabu ; Sai, Eirin ; Yamashita, Yoshihiro ; Asakage, Takahiro ; Miyazaki, Yasushi ; Kurokawa, Mineo ; Miyazono, Kohei ; Nimer, Stephen D ; Yamasoba, Tatsuya ; Mano, Hiroyuki. / Mutational landscape and antiproliferative functions of ELF transcription factors in human cancer. In: Cancer Research. 2016 ; Vol. 76, No. 7. pp. 1814-1824.
@article{544dc575df354fbf8e239dcf7c5b9b9c,
title = "Mutational landscape and antiproliferative functions of ELF transcription factors in human cancer",
abstract = "ELF4 (also known as MEF) is a member of the ETS family of transcription factors. An oncogenic role for ELF4 has been demonstrated in hematopoietic malignancies, but its function in epithelial tumors remains unclear. Here, we show that ELF4 can function as a tumor suppressor and is somatically inactivated in a wide range of human tumors. We identified a missense mutation affecting the trans activation potential of ELF4 in oral squamous cell carcinoma cells. Restoration of the trans activation activity through introduction of wild-type ELF4 significantly inhibited cell proliferation in vitro and tumor xenograft growth. Furthermore, we found that ELF1 and ELF2, closely related transcription factors to ELF4, also exerted antiproliferative effects in multiple cancer cell lines. Mutations in ELF1 and ELF2, as in ELF4, were widespread across human cancers, but were almost all mutually exclusive. Moreover, chromatin immunoprecipitation coupled with high-throughput sequencing revealed ELF4-binding sites in genomic regions adjacent to genes related to cell-cycle regulation and apoptosis. Finally, we provide mechanistic evidence that the antiproliferative effects of ELF4 were mediated through the induction of HRK, an activator of apoptosis, and DLX3, an inhibitor of cell growth. Collectively, our findings reveal a novel subtype of human cancer characterized by inactivating mutations in the ELF subfamily of proteins, and warrant further investigation of the specific settings where ELF restoration may be therapeutically beneficial.",
author = "Mizuo Ando and Masahito Kawazu and Toshihide Ueno and Daizo Koinuma and Koji Ando and Junji Koya and Keisuke Kataoka and Takahiko Yasuda and Hiroyuki Yamaguchi and Kazutaka Fukumura and Azusa Yamato and Manabu Soda and Eirin Sai and Yoshihiro Yamashita and Takahiro Asakage and Yasushi Miyazaki and Mineo Kurokawa and Kohei Miyazono and Nimer, {Stephen D} and Tatsuya Yamasoba and Hiroyuki Mano",
year = "2016",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-14-3816",
language = "English (US)",
volume = "76",
pages = "1814--1824",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Mutational landscape and antiproliferative functions of ELF transcription factors in human cancer

AU - Ando, Mizuo

AU - Kawazu, Masahito

AU - Ueno, Toshihide

AU - Koinuma, Daizo

AU - Ando, Koji

AU - Koya, Junji

AU - Kataoka, Keisuke

AU - Yasuda, Takahiko

AU - Yamaguchi, Hiroyuki

AU - Fukumura, Kazutaka

AU - Yamato, Azusa

AU - Soda, Manabu

AU - Sai, Eirin

AU - Yamashita, Yoshihiro

AU - Asakage, Takahiro

AU - Miyazaki, Yasushi

AU - Kurokawa, Mineo

AU - Miyazono, Kohei

AU - Nimer, Stephen D

AU - Yamasoba, Tatsuya

AU - Mano, Hiroyuki

PY - 2016/4/1

Y1 - 2016/4/1

N2 - ELF4 (also known as MEF) is a member of the ETS family of transcription factors. An oncogenic role for ELF4 has been demonstrated in hematopoietic malignancies, but its function in epithelial tumors remains unclear. Here, we show that ELF4 can function as a tumor suppressor and is somatically inactivated in a wide range of human tumors. We identified a missense mutation affecting the trans activation potential of ELF4 in oral squamous cell carcinoma cells. Restoration of the trans activation activity through introduction of wild-type ELF4 significantly inhibited cell proliferation in vitro and tumor xenograft growth. Furthermore, we found that ELF1 and ELF2, closely related transcription factors to ELF4, also exerted antiproliferative effects in multiple cancer cell lines. Mutations in ELF1 and ELF2, as in ELF4, were widespread across human cancers, but were almost all mutually exclusive. Moreover, chromatin immunoprecipitation coupled with high-throughput sequencing revealed ELF4-binding sites in genomic regions adjacent to genes related to cell-cycle regulation and apoptosis. Finally, we provide mechanistic evidence that the antiproliferative effects of ELF4 were mediated through the induction of HRK, an activator of apoptosis, and DLX3, an inhibitor of cell growth. Collectively, our findings reveal a novel subtype of human cancer characterized by inactivating mutations in the ELF subfamily of proteins, and warrant further investigation of the specific settings where ELF restoration may be therapeutically beneficial.

AB - ELF4 (also known as MEF) is a member of the ETS family of transcription factors. An oncogenic role for ELF4 has been demonstrated in hematopoietic malignancies, but its function in epithelial tumors remains unclear. Here, we show that ELF4 can function as a tumor suppressor and is somatically inactivated in a wide range of human tumors. We identified a missense mutation affecting the trans activation potential of ELF4 in oral squamous cell carcinoma cells. Restoration of the trans activation activity through introduction of wild-type ELF4 significantly inhibited cell proliferation in vitro and tumor xenograft growth. Furthermore, we found that ELF1 and ELF2, closely related transcription factors to ELF4, also exerted antiproliferative effects in multiple cancer cell lines. Mutations in ELF1 and ELF2, as in ELF4, were widespread across human cancers, but were almost all mutually exclusive. Moreover, chromatin immunoprecipitation coupled with high-throughput sequencing revealed ELF4-binding sites in genomic regions adjacent to genes related to cell-cycle regulation and apoptosis. Finally, we provide mechanistic evidence that the antiproliferative effects of ELF4 were mediated through the induction of HRK, an activator of apoptosis, and DLX3, an inhibitor of cell growth. Collectively, our findings reveal a novel subtype of human cancer characterized by inactivating mutations in the ELF subfamily of proteins, and warrant further investigation of the specific settings where ELF restoration may be therapeutically beneficial.

UR - http://www.scopus.com/inward/record.url?scp=84963593249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963593249&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-3816

DO - 10.1158/0008-5472.CAN-14-3816

M3 - Article

C2 - 26921333

AN - SCOPUS:84963593249

VL - 76

SP - 1814

EP - 1824

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -